Support The Moscow Times!

Drugmaker Plans IPO

Pharmsynthez plans to raise 500 million rubles ($16.3 million) in a stock market float this November, delivering a rare boost to the country’s flagging IPO market, the pharmaceutical company said Monday.

The funds will be used to build a new production plant in St. Petersburg and make strategic acquisitions overseas, the company said in a statement.

“There is enormous potential for growth in innovative medicine production in Russia, and Pharmsynthez is extremely well placed to capitalize on that growth,” chief executive Dmitry Genkin, who owns 25 percent, said in a statement.

A source familiar with the deal said about a 30 percent stake in the group could be floated.

(Reuters)


Read more

Independent journalism isn’t dead. You can help keep it alive.

As the only remaining independent, English-language news source reporting from Russia, The Moscow Times plays a critical role in connecting Russia to the world.

Editorial decisions are made entirely by journalists in our newsroom, who adhere to the highest ethical standards. We fearlessly cover issues that are often considered off-limits or taboo in Russia, from domestic violence and LGBT issues to the climate crisis and a secretive nuclear blast that exposed unknowing doctors to radiation.

As we approach the holiday season, please consider making a one-time donation — or better still a recurring donation — to The Moscow Times to help us continue producing vital, high-quality journalism about the world’s largest country.